Abstract 96P
Background
Next-generation sequencing (NGS) and genomic platforms provide crucial insights into tumor biology, guiding personalized treatments. Despite widespread adoption, their applicability in unselected patient populations lacks clarity. This study seeks to evaluate the clinical impact of a genomic platform in daily practice, assessing accessibility to targeted medications in a retrospective cohort from our center. Through real-world analysis, we aim to illuminate practical implications and challenges associated with genomic profiling in diverse patient populations.
Methods
A total of 165 consecutive patients who underwent NGS at the Italian Hospital of Buenos Aires from October 2019 to January 2022 were included. Demographic characteristics, primary tumor diagnoses, molecular alterations, and access to specific medication were evaluated. The ESMO Scale for Clinical Actionability of Molecular Targets (ESCAT) was used to categorize candidate molecular alterations for targeted treatment (CMATT).
Results
Among the 165 patients, 53% had identified alterations in the NGS panel, and 56% of those had potentially actionable mutations. The most common mutations included alterations in RAS, EGFR, BRAF, IDH1, and PI3K. Based on the ESCAT scale, 33% of mutations were categorized as type 1 (molecular alteration with recommended specific target treatment). However, 42% fell into type X (no evidence of clinical actionability). Access to specific medication was available for 30% of patients with potentially actionable mutations.
Conclusions
The prevalence of potentially actionable molecular alterations was high in the analyzed patients, but the accessibility to targeted therapies was limited. This highlights the importance of seeking strategies to increase patients' access to targeted treatments despite the usefulness of genetic panel sequencing as a valuable tool. By highlighting the disparity between the identification of actionable alterations and the challenges in accessing corresponding targeted therapies, our study emphasizes the importance of addressing barriers to treatment implementation and promoting equity in precision oncology.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.